Margaret A Madigan
Biographic Data
| ID | 9670945 |
|---|---|
| NAME | Margaret A Madigan |
| GIVEN NAMES | Margaret A |
| FAMILY NAME | Madigan |
| SIGNATURE | MADIGAN M A |
| AFFILIATIONS | i Department of Nutrigenomic and Personalized Medicine , Reward Deficiency Solutions LLC , San Diego , CA , US |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2012 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
The Emerging Crisis in Non-Prescribed Ketamine Use
BACKGROUND: Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. OBJECTIVE: This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines proposed mechanisms underlying its …
Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (Naat)TM Improves Behavioral Outcomes in a Residential Addiction Treatment Program
Substance use disorders (SUD) are inheritable and the culprit is hypodopaminergic function regulated by reward genes. We evaluated a natural dopaminergic agonist; KB220 intravenous (IV) and oral variants, to improve dopaminergic function in SUD. Our pilot experiment found a significant reduction of chronic symptoms, measured by the Chronic Abstinence Symptom Severity (CASS) Scale. The combined group (IV and oral) did significantly better than the…
No prominent works on this page.
Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (Naat)TM Improves Behavioral Outcomes in a Residential Addiction Treatment Program
Substance use disorders (SUD) are inheritable and the culprit is hypodopaminergic function regulated by reward genes. We evaluated a natural dopaminergic agonist; KB220 intravenous (IV) and oral variants, to improve dopaminergic function in SUD. Our pilot experiment found a significant reduction of chronic symptoms, measured by the Chronic Abstinence Symptom Severity (CASS) Scale. The combined group (IV and oral) did significantly better than the…
The Emerging Crisis in Non-Prescribed Ketamine Use
BACKGROUND: Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. OBJECTIVE: This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines proposed mechanisms underlying its …
Abstinence (1 work) · Addiction (1 work) · Anhedonia (1 work) · Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (1 work) · Attention Deficit Hyperactivity Disorder (1 work) · Clinical Psychology (1 work) · Clinical Psychology (1 work) · Dopamine (1 work) · Dopaminergic (1 work) · Drug (1 work)